HHS has awarded $8.3 million to the API Innovation Center to expand domestic manufacturing of two essential hospital medicines: metoprolol and propofol.
The funding will support end-to-end U.S. production of metoprolol for the first time in decades, according to a March 24 news release from the Administration for Strategic Preparedness and Response. With roughly 90% of cardiovascular drugs used in the U.S. sourced from India or China, the investment aims to reduce reliance on foreign suppliers and strengthen the domestic supply chain for medicines used in cardiovascular, surgical and intensive care settings.
The latest award brings total federal investment in the API Innovation Center to more than $22 million. It follows a $14 million grant in September 2024 to support domestic production of three other critical APIs.
The funds were awarded through the Biopharmaceutical Manufacturing Preparedness Consortium.
The post HHS invests $8.3M to boost supply of 2 drugs appeared first on Becker's Hospital Review | Healthcare News & Analysis.
Source: Read Original Article
